Perampanel for nonepileptic myoclonus in Angelman syndrome.

Brain Dev

Department of Pediatrics, Hokkaido University Hospital, Japan. Electronic address:

Published: May 2020

Background: Angelman syndrome (AS) is a neurodegenerative disorder caused by functional loss of the maternal ubiquitin-protein ligase 3A gene. Nonepileptic myoclonus, also described as tremulous movement, often occurs during puberty and increases in adulthood. The involuntary movement in AS has not been defined patho-physiologically and the drugs used such as levetiracetam and piracetam are not always effective. Recently, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonist, perampanel (PER), was used to alleviate myoclonus in progressive myoclonus epilepsy. Herein, we tested the efficacy of PER for nonepileptic myoclonus.

Methods And Results: Four patients with AS, aged from 20 to 40 years at the beginning of treatment, were enrolled in our study. All patients reported disruption to their daily lives from the myoclonus movement. They experienced mild to moderate improvement with the starting dose of 2 mg. The dose was increased to 4 mg in one patient to achieve sufficient efficacy, while two had their dose reduced to 1 mg due to dizziness or possible exacerbation of myoclonus. The last patient continued to take the starting dose. Follow-up over 16-20 months revealed a significant reduction in the severity of nonepileptic myoclonus in all patients.

Conclusion: Our study suggests that PER could be one of the promising drugs for nonepileptic myoclonus in AS.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.braindev.2020.02.007DOI Listing

Publication Analysis

Top Keywords

nonepileptic myoclonus
16
myoclonus
8
angelman syndrome
8
starting dose
8
perampanel nonepileptic
4
myoclonus angelman
4
syndrome background
4
background angelman
4
syndrome neurodegenerative
4
neurodegenerative disorder
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!